|
|
 Previous Article | Table of Contents | Next Article 
Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of
monoclonal gammopathies: correlation with diagnosis and disease status
U Dianzani, A Pileri, M Boccadoro, A Palumbo, P Pioppo, A Bianchi, A Camponi, G Fossati, S Battaglio and M Massaia
Department of Medicine and Experimental Oncology, University of Torino,
Italy.
The phenotypic pattern of peripheral blood T (PBT) lymphocytes was
correlated with diagnosis and clinical status in 63 patients with
monoclonal gammopathies (MGs). The numbers of lymphocytes expressing
activation and CD11 determinants were significantly increased in
suppressor/cytotoxic and helper/inducer subpopulations of patients with
multiple myeloma (MM) and MG of undetermined significance (MGUS). The
number of activated suppressor/cytotoxic cells was closely correlated with
diagnosis and disease status. These cells were significantly higher in MM
at diagnosis (160 +/- 88) than MGUS patients (61 +/- 79; P less than .01).
Their number decreased to MGUS levels in MM in stable remission (58 +/-
53), but not in MM with tumor progression (172 +/- 102; P less than .001).
In individual patients, part of these cells specifically adhered to dishes
precoated with the related M-protein. No monoclonal T-beta gene
rearrangement was detected in PBT and cytotoxic/suppressor subpopulations
from two patients with a large proportion of activated cells.
Volume 72,
Issue 3,
pp. 1064-1068,
09/01/1988
Copyright © 1988 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Orsini, R. Bellucci, E. P. Alyea, R. Schlossman, C. Canning, S. McLaughlin, P. Ghia, K. C. Anderson, and J. Ritz
Expansion of Tumor-specific CD8+ T Cell Clones in Patients with Relapsed Myeloma after Donor Lymphocyte Infusion
Cancer Res.,
May 15, 2003;
63(10):
2561 - 2568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Giuliani, S. Colla, R. Sala, M. Moroni, M. Lazzaretti, S. La Monica, S. Bonomini, M. Hojden, G. Sammarelli, S. Barille, et al.
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease
Blood,
December 15, 2002;
100(13):
4615 - 4621.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Dotti, B. Savoldo, P. Yotnda, D. Rill, and M. K. Brenner
Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40+ and CD40- plasmacytoma cells
Blood,
June 17, 2002;
100(1):
200 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Li, M. Bendandi, Y. Deng, C. Dunbar, N. Munshi, S. Jagannath, L. W. Kwak, and H. K. Lyerly
Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells
Blood,
October 15, 2000;
96(8):
2828 - 2833.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Pope, R. D. Brown, J. Gibson, E. Yuen, and D. Joshua
B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy
Blood,
August 15, 2000;
96(4):
1274 - 1279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Massaia, P. Borrione, S. Battaglio, S. Mariani, E. Beggiato, P. Napoli, C. Voena, A. Bianchi, M. Coscia, B. Besostri, et al.
Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy
Blood,
July 15, 1999;
94(2):
673 - 683.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
